-
-
-
-
-
-
-
Corbus Pharmaceuticals (CRBP) PT Lowered to $33 at Jefferies
-
-
-
-
-
-
-
Corbus Pharmaceuticals (CRBP) PT Raised to $40 at Mizuho
-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP)
-
-
-
-
-
-
-
Corbus Pharmaceuticals (CRBP) PT Lowered to $40 at H.C. Wainwright
-
-
-
-
-
-
-
Corbus Pharma (CRBP): CRB-701 A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO
-
-
-
-
-
-
-
Piper Sandler Starts Corbus Pharmaceuticals (CRBP) at Overweight
-
-
-
-
-
-
-
Oppenheimer Reiterates Corbus (CRBP) at Outperform, 'could weigh positively for CRBP with CRB-913's substantially lower CNS penetration'
-
419,036 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

